MedTrace Logo

The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans

NCT04815213 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-01-28

No results posted yet for this study

Summary

Autologous bone marrow-derived mesenchymal cells will be injected into patients diagnosed with premature ovarian failure

Conditions

  • Premature Ovarian Failure

Interventions

BIOLOGICAL

expanded autologous bone marrow derived MSC Intravaginally

Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary

BIOLOGICAL

expanded autologous bone marrow derived MSC Laporoscopic

Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary

BIOLOGICAL

EV

Extracellular vesicles injection

Sponsors & Collaborators

  • University of Jordan

    lead OTHER

Principal Investigators

  • Dr Abdalla Awidi, MD · Cell therapy center

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2025-01-31
Completion
2027-01-31

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04815213 on ClinicalTrials.gov